A detailed history of Level Four Advisory Services, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Level Four Advisory Services, LLC holds 7,175 shares of VRTX stock, worth $3.61 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
7,175
Previous 7,524 4.64%
Holding current value
$3.61 Million
Previous $3.15 Million 6.93%
% of portfolio
0.16%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $137,090 - $169,449
-349 Reduced 4.64%
7,175 $3.36 Million
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $101,107 - $110,627
248 Added 3.41%
7,524 $3.15 Million
Q4 2023

Feb 08, 2024

SELL
$343.0 - $410.68 $99,470 - $119,097
-290 Reduced 3.83%
7,276 $2.96 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $11,836 - $12,686
35 Added 0.46%
7,566 $2.63 Million
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $11,004 - $12,316
35 Added 0.47%
7,531 $2.65 Million
Q1 2023

Jun 05, 2023

SELL
$283.23 - $323.1 $117,540 - $134,086
-415 Reduced 5.25%
7,496 $2.36 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $205,461 - $231,144
-719 Reduced 8.33%
7,911 $2.28 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $71,743 - $80,048
-262 Reduced 2.95%
8,630 $2.5 Million
Q2 2022

Aug 08, 2022

SELL
$234.96 - $292.55 $99,153 - $123,456
-422 Reduced 4.53%
8,892 $2.51 Million
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $19,263 - $22,704
87 Added 0.94%
9,314 $2.43 Million
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $101,957 - $128,707
-576 Reduced 5.88%
9,227 $2.03 Million
Q3 2021

Oct 12, 2021

BUY
$181.39 - $202.99 $1.78 Million - $1.99 Million
9,803 New
9,803 $1.78 Million
Q3 2020

Nov 02, 2020

SELL
$255.65 - $303.1 $221,137 - $262,181
-865 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$225.48 - $295.8 $195,040 - $255,867
865 New
865 $248,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Level Four Advisory Services, LLC Portfolio

Follow Level Four Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Level Four Advisory Services, LLC with notifications on news.